Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No TWEAK for COPD.
Lazaar AL, Miller BE, Francombe G, Duvoix A, Natanek SA, Polkey MI. Lazaar AL, et al. Eur Respir J. 2013 Oct;42(4):1142-4. doi: 10.1183/09031936.00035413. Eur Respir J. 2013. PMID: 24081764 Free article. No abstract available.
Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.
Lazaar AL, Miller BE, Tabberer M, Yonchuk J, Leidy N, Ambery C, Bloomer J, Watz H, Tal-Singer R. Lazaar AL, et al. Eur Respir J. 2018 Oct 4;52(4):1801020. doi: 10.1183/13993003.01020-2018. Print 2018 Oct. Eur Respir J. 2018. PMID: 30139779 Free article. Clinical Trial. No abstract available.
The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers.
Miller BE, Smart K, Mistry S, Ambery CL, Bloomer JC, Connolly P, Sanderson D, Shreeves T, Smith R, Lazaar AL. Miller BE, et al. Among authors: lazaar al. Eur J Drug Metab Pharmacokinet. 2014 Sep;39(3):173-81. doi: 10.1007/s13318-014-0179-8. Epub 2014 Feb 7. Eur J Drug Metab Pharmacokinet. 2014. PMID: 24504700 Free PMC article. Clinical Trial.
Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.
Bloomer JC, Ambery C, Miller BE, Connolly P, Garden H, Henley N, Hodnett N, Keel S, Kreindler JL, Lloyd RS, Matthews W, Yonchuk J, Lazaar AL. Bloomer JC, et al. Among authors: lazaar al. Eur J Pharm Biopharm. 2017 Aug;117:224-231. doi: 10.1016/j.ejpb.2017.03.023. Epub 2017 Apr 3. Eur J Pharm Biopharm. 2017. PMID: 28385615 Clinical Trial.
Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort.
Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Lomas DA, et al. Thorax. 2008 Dec;63(12):1058-63. doi: 10.1136/thx.2008.102574. Epub 2008 Aug 29. Thorax. 2008. PMID: 18757456
55 results